Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685698 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
A Phase 2 study of Diabetic Foot Infections, sponsored by TaiGen Biotechnology Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 16
- Study locations
NCT00685698 is a Phase 2 study of Diabetic Foot Infections that has completed, run by TaiGen Biotechnology Co.. The registered enrollment target is 40 participants. The trial reports 16 study locations across 5 states.
The verdict
NCT00685698, a Phase 2 study of Diabetic Foot Infections, has completed, sponsored by TaiGen Biotechnology Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 16
- Study locations
Study Summary
Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Conditions Studied
Interventions
- DRUG TG-873870 (Nemonoxacin)
Study Locations (16)
Other
- Chang Gung Memorial Hospital- Kaoshiung, Taiwan - Kaohsiung City
- Cheng Ching Hospital, Taichung, Taiwan - Taichung
- Chi-Mei Medical Center, Tainan, Taiwan - Tainan
- Cardinal Tien Hospital (CTH), Taiwan - Taipei
- Tri-Service General Hospital, Taipei, Taiwan - Taipei
- Wan Fang Hospital - Taipei
- Cheng-Gung Memorial Hospital - LinKou, Taiwan - Taoyuan District
- Faculty of Medicine, Khon Kaen University - Khon Kaen
Gauteng
- Eastmed Academic Clinical Trial Center - East Lynne
- Jubilee Clinical Trial Center - Hammanskraal
- Montana Hospital - Pretoria
- Park Medical Center - Witbank
California
- HealthCare Partners - Montebello
- HealthCare Partners - Pasadena
Iowa
- The Amputation Prevention Center at Broadlawns Medical Center - Des Moines
Port Elizabeth
- Mercantile Clinical Trial Center - Korsten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685698
The ClinicalTrials.gov registry entry for NCT00685698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TaiGen Biotechnology Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Foot Infections appearing as the primary indexed condition, and to 1 intervention - of which TG-873870 (Nemonoxacin) is the first listed.
NCT00685698 reports 16 study locations spanning 5 distinct geographic areas - top geographies include Other, Gauteng, California.
Frequently Asked Questions
What is clinical trial NCT00685698 about?
NCT00685698 is a clinical study titled "Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections". Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
What is the current status of trial NCT00685698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-06. Estimated completion is 2009-06.
What conditions does trial NCT00685698 study?
This clinical trial studies the following conditions: Diabetic Foot Infections.
What interventions are being tested in trial NCT00685698?
The interventions under investigation include: TG-873870 (Nemonoxacin) (DRUG).
Who is sponsoring clinical trial NCT00685698?
This trial is sponsored by TaiGen Biotechnology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00685698 being conducted?
This trial has 16 study locations across California, Iowa, Gauteng, Port Elizabeth. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.